{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:24:24Z","timestamp":1790540664782,"version":"4.1.0"},"reference-count":48,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Foundation for Innovative New Diagnostics"},{"name":"German Federal Ministry of Education and Research"},{"DOI":"10.13039\/501100007729","name":"Dutch Ministry of Foreign Affairs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007729","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Australian Department of Foreign Affairs and Trade"},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI111397"],"award-info":[{"award-number":["AI111397"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2021,2,18]]},"abstract":"<jats:p>\n                    We describe the design, development, analytical performance, and a limited clinical evaluation of the 10-color Xpert MTB\/XDR assay (CE-IVD only, not for sale in the United States). This assay is intended as a reflex test to detect resistance to isoniazid (INH), fluoroquinolones (FLQ), ethionamide (ETH), and second-line injectable drugs (SLIDs) in unprocessed sputum samples and concentrated sputum sediments which are positive for\n                    <jats:named-content content-type=\"genus-species\">Mycobacterium tuberculosis<\/jats:named-content>\n                    .\n                  <\/jats:p>","DOI":"10.1128\/jcm.02314-20","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T08:45:34Z","timestamp":1607589934000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":89,"title":["Xpert MTB\/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum"],"prefix":"10.1128","volume":"59","author":[{"given":"Yuan","family":"Cao","sequence":"first","affiliation":[{"name":"New Jersey Medical School, Rutgers University, Newark, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heta","family":"Parmar","sequence":"additional","affiliation":[{"name":"New Jersey Medical School, Rutgers University, Newark, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv L.","family":"Gaur","sequence":"additional","affiliation":[{"name":"Cepheid Inc., Sunnyvale, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Lieu","sequence":"additional","affiliation":[{"name":"Cepheid Inc., Sunnyvale, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobana","family":"Raghunath","sequence":"additional","affiliation":[{"name":"Cepheid Inc., Sunnyvale, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nova","family":"Via","sequence":"additional","affiliation":[{"name":"Cepheid Inc., Sunnyvale, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Battaglia","sequence":"additional","affiliation":[{"name":"San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6415-1535","authenticated-orcid":true,"given":"Daniela M.","family":"Cirillo","sequence":"additional","affiliation":[{"name":"San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Denkinger","sequence":"additional","affiliation":[{"name":"Foundation for Innovative New Diagnostics, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Georghiou","sequence":"additional","affiliation":[{"name":"Foundation for Innovative New Diagnostics, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kwiatkowski","sequence":"additional","affiliation":[{"name":"Cepheid Inc., Sunnyvale, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Persing","sequence":"additional","affiliation":[{"name":"Cepheid Inc., Sunnyvale, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-1571","authenticated-orcid":true,"given":"David","family":"Alland","sequence":"additional","affiliation":[{"name":"New Jersey Medical School, Rutgers University, Newark, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumitesh","family":"Chakravorty","sequence":"additional","affiliation":[{"name":"New Jersey Medical School, Rutgers University, Newark, New Jersey, USA"},{"name":"Cepheid Inc., Sunnyvale, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Global tuberculosis report 2019","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. 2019. Global tuberculosis report 2019. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx506"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz106"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907847"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30691-6"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902129"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126065"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01550-17"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41479-018-0049-2"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01771-16"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614915"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/mmi.12476"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0907925106"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033275"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01354-2017"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01550-10"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02775-15"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01049-15"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00287-09"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix556"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv360"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00092-19"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0184-0"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0732-8893(03)00132-9"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389200218666171031121905"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.07.004"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02271-10"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119628"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.47.12.3799-3805.2003"},{"key":"e_1_3_3_31_2","volume-title":"Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. 2018. Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB. WHO\/CDS\/TB\/20185. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00812-17"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01463-09"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.83.5.409"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.29.11.2578-2586.1991"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01662-16"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2014.21"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120470"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039754"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro.2018.8"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2517"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05793-11"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02066-13"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176522"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep41410"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00907-19"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00112-06"},{"key":"e_1_3_3_48_2","volume-title":"Global tuberculosis report 2017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. 2017. Global tuberculosis report 2017. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_49_2","volume-title":"New study 31\/A5349 on the treatment of drug-susceptible TB","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. 2020. New study 31\/A5349 on the treatment of drug-susceptible TB. World Health Organization, Geneva, Switzerland."}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.02314-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.02314-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T05:54:48Z","timestamp":1646459688000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.02314-20"}},"subtitle":[],"editor":[{"given":"Christine Y.","family":"Turenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2,18]]}},"alternative-id":["10.1128\/JCM.02314-20"],"URL":"https:\/\/doi.org\/10.1128\/jcm.02314-20","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.09.08.288787","asserted-by":"object"}]},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"2020-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02314-20"}}